Panaecin is under clinical development by Aridis Pharmaceuticals and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Panaecin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Panaecin overview
Panaecin (gallium citrate) is under development for the treatment of bacterial lung infections including Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). It is administered to the lung by inhalation route and through topical route in wound infections. Panaecin is developed based on inhalable aerosols technology. It was also under development for the treatment of wounds infection, ventilator-associated pneumonia, S. aureus, methicillin-resistant S. aureus (MRSA), B. cepacia, cystic fibrosis and COPD exacerbation.
Aridis Pharmaceuticals overview
Aridis Pharmaceuticals (Aridis) is a biopharmaceutical company that develops targeted immunotherapy using fully human monoclonal antibodies. Its technology platforms include ?PEX and MabIgX which identifies human-derived monoclonal antibodies for infectious diseases and apply them as therapeutic agents that neutralize invading pathogens. The company’s pipeline products include AR-301, AR-320 mAb which treats s.aureus ventilator assoc. pneumonia (VAP); AR-501 for the treatment of cystic fibrosis lung infections; AR-701 mAbs for COVID-19; AR-401 mAb treats bacteremia. Its partnered products include AR-105 mAb, AR-101 mAb treats pneumonia and AR-201 mAb for respiratory syncytial virus. Aridis is headquartered in San Jose, California, the US.
For a complete picture of Panaecin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
